EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice

Lingzhi Long, Qi Huang, Tao Song, Zhijie Dai

Journal of Applied Biomedicine · 2024

DOI: 10.32725/jab.2024.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Biomedicine, 2024. Verfasst von Lingzhi Long und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Department of Pharmacy, Changsha, China. Hauptthemen laut MEDLINE: Insulin Resistance, Dyslipidemias, Inositol, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myo-inositol (MI), present in a variety of foods, is essential in several important processes of cell physiology. In this study, we explored the protective effects of MI against hyperglycemia and dyslipidemia in db/db mice, a typical animal model of type 2 diabetes mellitus (T2DM). MI supplement effectively suppressed the high plasma glucose and insulin levels and markedly relieved the insulin resistance (IR) in the db/db mice, comparable to metformin's effects. In MIN6 pancreatic β cells, MI also restrained the upsurge of insulin secretion stimulated by high-concentration glucose but had no impact on the promoted cell proliferation. Moreover, MI abated the enhanced plasma triglyceride and total cholesterol levels in the db/db mice. Notably, the lipid droplet formation of mesenchymal stem cells (MSCs) from db/db mice was significantly diminished after the treatment of MI, indicating that MI could effectively inhibit the differentiation of db/db mouse MSCs into adipocytes. However, MI regretfully failed to control obesity in db/db mice. This work proved that MI significantly helped db/db mice's metabolic disorders, indicating that MI has potential as an effective adjunctive treatment for hyperglycemia and dyslipidemia in T2DM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceDyslipidemiasInositolDiabetes Mellitus, Type 2AnimalsMiceMaleInsulinMesenchymal Stem CellsBlood GlucoseInsulin-Secreting CellsAdipocytesHyperglycemia

Stichwörter der Autor:innen

DyslipidemiaHyperglycemiaInsulin resistanceMyo-inositoldb/db mice

Substanzen

InositolInsulinBlood Glucose

Autor:innen und Institutionen

  • Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Department of Pharmacy, Changsha, China.
  • Central South University, Xiangya Hospital, Department of Neurosurgery, Changsha, China.
  • The Second Xiangya Hospital of Central South University, Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Changsha, China.

Förderung

  • Hunan Provincial Natural Science Foundation of China

Zitieren

APA

Long, L., Huang, Q., Song, T., & Dai, Z. (2024). Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice. Journal of Applied Biomedicine. https://doi.org/10.32725/jab.2024.009

Vancouver

Long L, Huang Q, Song T, Dai Z. Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice. Journal of Applied Biomedicine. 2024. doi:10.32725/jab.2024.009

BibTeX
@article{Long2024,
  author = {Long, Lingzhi and Huang, Qi and Song, Tao and Dai, Zhijie},
  title = {Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice},
  journal = {Journal of Applied Biomedicine},
  year = {2024},
  doi = {10.32725/jab.2024.009}
}
Kostenlos starten →